Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes

Myelodysplastic syndromes (MDS) are characterized by recurrent somatic alterations often affecting components of RNA splicing machinery. Mutations of splice factors SF3B1, SRSF2, ZRSR2 and U2AF1 occur in >50% of MDS. To assess the impact of spliceosome mutations on splicing and to identify common pathways/genes affected by distinct mutations, we performed RNA‐sequencing of MDS bone marrow samples harboring spliceosome mutations (including hotspot alterations of SF3B1, SRSF2 and U2AF1; small deletions of SRSF2 and truncating mutations of ZRSR2), and devoid of other common co‐occurring mutations. We uncover the landscape of splicing alterations in each splice factor mutant MDS and demonstrate that small deletions in SRSF2 cause highest number of splicing alterations compared with other spliceosome mutations. Although the mis‐spliced events observed in different splice factor mutations were largely non‐overlapping, a subset of genes, including EZH2, were aberrantly spliced in multiple mutant groups. We also verified aberrant splicing of key genes USP9X, USP24 (deubiquitinating enzymes), LUC7L2 (splice factor) and EED (PRC2 component) in MDS harboring small deletions of SRSF2. Pathway analysis revealed that mis‐spliced genes in different mutant groups were enriched in RNA splicing and transport as well as several signaling cascades, suggesting converging biological consequences downstream of distinct spliceosome mutations. Our study reveals splicing signatures of each splice factor mutation and identifies shared and distinct sets of mis‐spliced genes and affected biological processes in different spliceosome mutant MDS.

[1]  S. Shen,et al.  The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia , 2018, Leukemia.

[2]  A. Gavin,et al.  Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. , 2018, Blood.

[3]  M. Cazzola,et al.  Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia , 2018, Nature Communications.

[4]  G. Stefani,et al.  SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells , 2018, Leukemia.

[5]  S. Ogawa,et al.  Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. , 2018, Blood.

[6]  C. Haferlach,et al.  Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms , 2017, Leukemia.

[7]  M. Cazzola,et al.  The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes , 2017, The Journal of clinical investigation.

[8]  Christopher M. DeBoever,et al.  Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators , 2016, RNA.

[9]  Michelle C. Chen,et al.  Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. , 2016, Cancer cell.

[10]  D. Kent,et al.  Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts , 2016, Leukemia.

[11]  S. Miyano,et al.  Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia , 2016, Leukemia.

[12]  S. Roman-Roman,et al.  Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage , 2016, Nature Communications.

[13]  A. Tefferi,et al.  Myelodysplastic syndromes: Contemporary review and how we treat , 2016, American journal of hematology.

[14]  M. Warmuth,et al.  Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. , 2015, Cell reports.

[15]  Alexander Dobin,et al.  Mapping RNA‐seq Reads with STAR , 2015, Current protocols in bioinformatics.

[16]  Alexander V Penson,et al.  Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities , 2015, Proceedings of the National Academy of Sciences.

[17]  Xiang-Dong Fu,et al.  SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing , 2015, Molecular and Cellular Biology.

[18]  R. Fulton,et al.  Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. , 2015, Cancer cell.

[19]  H. Deeg,et al.  SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. , 2015, Cancer cell.

[20]  R. Reed,et al.  Premature termination codons are recognized in the nucleus in a reading-frame-dependent manner , 2015, Cell Discovery.

[21]  J. Gécz,et al.  La FAM fatale: USP9X in development and disease , 2015, Cellular and Molecular Life Sciences.

[22]  S. Miyano,et al.  Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome , 2014, Nature Communications.

[23]  M Cazzola,et al.  Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells , 2014, Leukemia.

[24]  L. Ding,et al.  U2AF1 Mutations Alter Sequence Specificity of pre-mRNA Binding and Splicing , 2014, Leukemia.

[25]  Philip Bradley,et al.  U2AF1 mutations alter splice site recognition in hematological malignancies , 2014, bioRxiv.

[26]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[27]  H. Aburatani,et al.  Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders , 2013, The Journal of experimental medicine.

[28]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[29]  J. Maciejewski,et al.  Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. , 2013, Blood.

[30]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[31]  A. Lane,et al.  Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies , 2013, Blood Cancer Journal.

[32]  B. Ko,et al.  The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. , 2012, Blood.

[33]  S. Ogawa,et al.  SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). , 2012, Blood.

[34]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[35]  Xiaomei Ma Epidemiology of myelodysplastic syndromes. , 2012, The American journal of medicine.

[36]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[37]  Michael Heuser,et al.  Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.

[38]  A. Jankowska,et al.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.

[39]  Claude Preudhomme,et al.  Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. , 2012, Blood.

[40]  Franco Locatelli,et al.  Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. , 2012, Blood.

[41]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[42]  J. Tamburini,et al.  LKB1/AMPK/mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology , 2011, Cell cycle.

[43]  M. Kondo,et al.  Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development , 2011, Immunologic research.

[44]  B. Viollet,et al.  The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. , 2010, Blood.

[45]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[46]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[47]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[48]  David Komander,et al.  Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.

[49]  D. Johnson,et al.  Signal transduction pathways that contribute to myeloid differentiation , 2007, Leukemia.

[50]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  H. Kantarjian,et al.  Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions , 2015, Current Oncology Reports.

[52]  David P Steensma,et al.  Myelodysplastic Syndromes: Diagnosis and Treatment. , 2015, Mayo Clinic proceedings.

[53]  J. Bennett,et al.  The myelodysplastic syndromes: diagnosis and treatment. , 2006, Mayo Clinic proceedings.

[54]  James Stévenin,et al.  Broad specificity of SR (serine/arginine) proteins in the regulation of alternative splicing of pre-messenger RNA. , 2004, Progress in nucleic acid research and molecular biology.